At the time of writing, Cue Biopharma Inc [CUE] stock is trading at $1.68, up 38.84%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CUE shares have gain 38.84% over the last week, with a monthly amount glided 220.61%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Cue Biopharma Inc [NASDAQ: CUE] stock has seen the most recent analyst activity on March 13, 2024, when Jefferies initiated its Buy rating and assigned the stock a price target of $6. On November 21, 2022, Piper Sandler initiated with a Overweight rating and assigned a price target of $7 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $20 on January 13, 2022. Craig Hallum initiated its recommendation with a Buy and recommended $28 as its price target on January 03, 2022. Berenberg started tracking with a Buy rating for this stock on November 24, 2020, and assigned it a price target of $30. In a note dated April 09, 2020, Stifel initiated an Buy rating and provided a target price of $21 on this stock.
For the past year, the stock price of Cue Biopharma Inc fluctuated between $0.45 and $3.25. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. Cue Biopharma Inc [NASDAQ: CUE] shares were valued at $1.68 at the most recent close of the market. An investor can expect a potential return of 197.62% based on the average CUE price forecast.
Analyzing the CUE fundamentals
According to Cue Biopharma Inc [NASDAQ:CUE], the company’s sales were 8.30M for trailing twelve months, which represents an 92.33% jump. Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at -5.8%, Pretax Profit Margin comes in at -5.66%, and Net Profit Margin reading is -5.66%. To continue investigating profitability, this company’s Return on Assets is posted at -1.11, Equity is -1.43 and Total Capital is -1.86. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.43.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.3407 points at the first support level, and at 1.0015 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.9591, and for the 2nd resistance point, it is at 2.2383.
Ratios To Look Out For
It is important to note that Cue Biopharma Inc [NASDAQ:CUE] has a current ratio of 2.06. In addition, the Quick Ratio stands at 2.06 and the Cash Ratio stands at 1.82. Considering the valuation of this stock, the price to sales ratio is 12.19, the price to book ratio is 3.78.
